Despite stopping semaglutide’s FLOW study in patients with type 2 diabetes and chronic kidney disease (CKD) early for efficacy on October 10, Novo Nordisk A/S has decided to buy another, differently acting, product for a similar use (Also see "The FLOW Of Novo Nordisk's Semaglutide Success Rolls Into Kidney Disease" - Scrip, 11 October, 2023.). It has bought the non-steroidal mineralocorticoid receptor antagonist (MRA) ocedurenone from KBP BioSciences Co Ltd for up to $1.3bn.
Novo Nordisk heeds KBP Biosciences’ CLARION call
Novo Nordisk’s metabolic juggernaut semaglutide is known to work in chronic kidney disease – but the group appears to want a back-up plan.
More from Business
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.